

MLN120B

Catalog No: tcsc1291



Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg



Specifications

CAS No:

783348-36-7

Formula:

$C_{19}H_{15}ClN_4O_2$

Pathway:

NF-κB

Target:

IKK

Purity / Grade:

>98%

Solubility:

DMSO : ≥ 31 mg/mL (84.51 mM)

Alternative Names:

ML120B

Observed Molecular Weight:


366.8

Product Description

MLN120B is a specific, ATP competitive **IKK β** inhibitor with an **IC₅₀** of 60 nM.

In Vitro: MLN120B inhibits both baseline and tumor necrosis factor- α -induced nuclear factor- κ B activation, associated with down-regulation of I κ B α and p65 nuclear factor- κ B phosphorylation in multiple myeloma cells. MLN120B almost completely blocks stimulation of MM.1S, U266, and INA6 cell growth, as well as IL-6 secretion from BMSCs, induced by multiple myeloma cell adherence to BMSCs^[1]. MLN120B shows an inhibitory effect on LPS induced NF- κ B activation in RAW267.4 cells. The IC₅₀ values of MLN120B is 1.4, 14.8 or 27.3 μ M for NF- κ B2-luc2, IL8-luc2 or TNF-AIP3-luc2 reporter transfected cells, respectively^[3].

In Vivo: MLN120B (50 mg/kg, p.o.) inhibits human multiple myeloma cell growth in vivo^[1]. MLN120B (12 mg/kg twice daily, p.o.) inhibits paw swelling in a dose-dependent manner and offers significant protection against arthritis-induced weight loss as well as cartilage and bone erosion. NF- κ B activity in arthritic joints is reduced after MLN120B administration^[2].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!